Published in J Pediatr on May 01, 1990
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (1996) 13.91
The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev (2010) 4.22
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.04
Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax (1992) 1.97
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr (2008) 1.96
Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol (2004) 1.80
Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med (2014) 1.66
Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun (1999) 1.54
Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS One (2013) 1.49
Role of energy metabolism in conversion of nonmucoid Pseudomonas aeruginosa to the mucoid phenotype. Infect Immun (1992) 1.37
Cystic fibrosis. 2. Lung injury in cystic fibrosis. Thorax (1990) 1.37
Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis. J Clin Microbiol (2015) 1.29
IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis. Arch Dis Child (1992) 1.26
Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis. Infect Immun (2003) 1.20
Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax (2005) 1.20
Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax (2002) 1.13
Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet (2008) 1.12
Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother (2001) 1.10
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol (2011) 1.10
Capillary electrophoresis-single-strand conformation polymorphism analysis for rapid identification of Pseudomonas aeruginosa and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol (1999) 1.08
Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc (2007) 1.07
Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Thorax (2003) 1.06
Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax (1998) 1.06
Comparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of Pseudomonas aeruginosa in sputum of cystic fibrosis patients. BMC Microbiol (2009) 1.05
An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun (2008) 1.03
Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosis. J Med Genet (2006) 1.02
Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review. Health Qual Life Outcomes (2005) 1.02
Growth and growth charts in cystic fibrosis. J R Soc Med (2003) 0.98
Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur J Clin Pharmacol (2004) 0.98
Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. J Cyst Fibros (2012) 0.97
Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis (2014) 0.94
Lung function from infancy to school age in cystic fibrosis. Arch Dis Child (1995) 0.94
Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis. Respir Res (2006) 0.93
Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study. JRSM Short Rep (2013) 0.93
Utility of gram stain in evaluation of sputa from patients with cystic fibrosis. J Clin Microbiol (1994) 0.93
Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. J Clin Microbiol (2014) 0.90
Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrob Agents Chemother (2013) 0.88
Genetic influences on cystic fibrosis lung disease severity. Front Pharmacol (2013) 0.88
Comparison of culture and qPCR for the detection of Pseudomonas aeruginosa in not chronically infected cystic fibrosis patients. BMC Microbiol (2010) 0.87
The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis--prognostic significance. Eur J Pediatr (1995) 0.87
Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr (2013) 0.86
Detection of Pseudomonas aeruginosa in sputum headspace through volatile organic compound analysis. Respir Res (2012) 0.85
Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data. Eur J Health Econ (2014) 0.84
The relationship of systemic inflammation to prior hospitalization in adult patients with cystic fibrosis. BMC Pulm Med (2012) 0.83
Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients. BMC Pulm Med (2015) 0.81
Cystic fibrosis. Thorax (2001) 0.80
Targeted therapies to improve CFTR function in cystic fibrosis. Genome Med (2015) 0.79
Smell in cystic fibrosis. Eur Arch Otorhinolaryngol (2012) 0.78
Health-related quality of life in Cystic Fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study. JRSM Short Rep (2012) 0.77
Segregation is good for patients with cystic fibrosis. J R Soc Med (2008) 0.77
Genetic determinants of Pseudomonas aeruginosa colonization in cystic fibrosis patients in Canada. Eur J Clin Microbiol Infect Dis (1998) 0.77
Phenotypic conversion of Pseudomonas aeruginosa. J Clin Microbiol (1991) 0.75
A cross-sectional study of growth, nutritional status and body proportions in children and adolescents at a medical center specializing in the treatment of cystic fibrosis in Poland. Arch Med Sci (2015) 0.75
Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis. BMC Pulm Med (2015) 0.75
Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis. Infect Drug Resist (2010) 0.75
Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis? BMC Infect Dis (2017) 0.75
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Management of asthma: a consensus statement. Arch Dis Child (1989) 7.04
Prediction of mortality in patients with cystic fibrosis. N Engl J Med (1992) 5.46
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). N Engl J Med (1990) 4.70
A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol (1988) 4.41
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr (1997) 3.38
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Bronchial reactivity in cystic fibrosis. Pediatrics (1978) 2.70
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
Standards of pulmonary function in children. Am Rev Respir Dis (1969) 2.56
The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med (1995) 2.49
Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet (1992) 2.48
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics. J Pediatr (1981) 2.41
Pulmonary function abnormalities in symptom-free children after bronchiolitis. Pediatrics (1977) 2.32
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med (1984) 2.22
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet (1987) 2.05
Five- to seven-year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis (1976) 2.03
Pulmonary function and bronchial hyperreactivity in long-term survivors of bronchopulmonary dysplasia. Pediatrics (1981) 2.00
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
Ultrastructure of airways in children with asthma. Histopathology (1978) 1.97
A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. J Pediatr (2000) 1.93
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest (1992) 1.80
Hepatic abscess and cystic fibrosis. Postgrad Med J (1988) 1.77
Role of conventional physiotherapy in cystic fibrosis. J Pediatr (1988) 1.75
Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology (1988) 1.75
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr (1995) 1.70
The HIV information project for transfusion recipients a decade after transfusion. Arch Pediatr Adolesc Med (1995) 1.70
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis (1979) 1.67
DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. Am J Hum Genet (1989) 1.66
Diabetes mellitus in patients with cystic fibrosis: effect on survival. Pediatrics (1990) 1.65
Sex differences in habitual physical activity and lung function decline in children with cystic fibrosis. J Pediatr (2005) 1.64
Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr (1982) 1.64
Increased incidence of bronchial reactivity in children with a history of bronchiolitis. J Pediatr (1981) 1.62
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
Clinical and physiological assessment of asthmatic children treated with beclomethasone dipropionate. J Allergy Clin Immunol (1976) 1.59
Transit time analysis of the forced expiratory vital capacity in cystic fibrosis. Am Rev Respir Dis (1976) 1.58
Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. J Pediatr (1995) 1.56
Severe acute asthma in a pediatric intensive care unit: six years' experience. Pediatrics (1989) 1.54
Volume of isoflow. A new test in detection of mild abnormalities of lung mechanics. Am Rev Respir Dis (1974) 1.53
Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med (1985) 1.52
Pulmonary function in children with asthma at acute attack and symptom-free status. Am Rev Respir Dis (1969) 1.52
Energy expenditure of patients with cystic fibrosis. J Pediatr (1987) 1.51
The approach to chronic cough in childhood. Ann Allergy (1988) 1.51
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
Mucociliary tracheal transport rates in man. J Appl Physiol (1975) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand (2003) 1.49
Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene? Clin Genet (2009) 1.47
CFTR gene variant for patients with congenital absence of vas deferens. Am J Hum Genet (1995) 1.47
Shwachman syndrome: phenotypic manifestations of sibling sets and isolated cases in a large patient cohort are similar. J Pediatr (1999) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Lung function in children following repair of tracheoesophageal fistula. J Pediatr (1979) 1.46
Airway closure in children. J Appl Physiol (1972) 1.45
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
Hypoalbuminemia at initial examination in patients with cystic fibrosis. J Pediatr (1989) 1.45
Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut (2003) 1.45
Childhood asthma: a rational approach to treatment. Ann Allergy (1990) 1.44
Spacers in childhood asthma--is there one for all occasions? Ann Allergy (1990) 1.43
A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res (1985) 1.42
Maximal expiratory flows generated by rapid chest compression following end-inspiratory occlusion or expiratory clamping in young children. Eur Respir J (1995) 1.41
Treating HIV encephalopathy with antiretroviral therapy: a clinical case demonstrating the success of HAART. Clin Infect Dis (2004) 1.41
Intravenous Immunoglobulins in MS. Int MS J (2005) 1.41
Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet (1999) 1.41
Chronic recurrent multifocal osteomyelitis: a noninfectious inflammatory process. Pediatr Infect Dis J (1987) 1.37
Transcutaneous monitoring of oxygenation: what is normal? J Pediatr (1986) 1.37
Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. J Pediatr (1989) 1.37
Changes in ventilation and chest wall mechanics during sleep in normal adolescents. J Appl Physiol Respir Environ Exerc Physiol (1981) 1.36
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood (2000) 1.35
Spacing devices and metered-dose inhalers in childhood asthma. J Pediatr (1985) 1.35